Ajanta Pharma Stock Screener | Share Price & Fundamental Analysis
AJANTPHARM
Pharmaceuticals
Share Price NSE
₹2805.10
▼
-2.80 (-0.10%)
Share Price BSE
₹2803.50
▼
-17.95 (-0.64%)
Track Ajanta Pharma share price live with TickJournal's free stock screener.
Analyze Ajanta Pharma share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Ajanta Pharma Market Cap
₹35,080.67 Cr.
AJANTPHARM P/E Ratio (TTM)
35.46
Ajanta Pharma P/B Ratio
8.34
EPS (TTM)
₹73.56
Dividend Yield
0.98%
Debt to Equity
0.01
AJANTPHARM 52 Week High
₹3119.50
Ajanta Pharma 52 Week Low
₹2374.45
Operating Margin
28.00%
Profit Margin
19.57%
AJANTPHARM Revenue (TTM)
₹1,400.00
EBITDA
₹407.00
Net Income
₹274.00
Total Assets
₹5,015.00
Total Equity
₹3,790.00
Ajanta Pharma Share Price History - Stock Screener Chart
Screen AJANTPHARM historical share price movements with interactive charts. Analyze price trends and patterns.
Ajanta Pharma Company Profile - Fundamental Screener
Screen Ajanta Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AJANTPHARM shares.
Ajanta Pharma is an Indian specialty pharmaceutical company focusing on branded generic products. It operates in India, Asia, Africa, and the USA, offering a range of therapeutic products including cardiology, dermatology, ophthalmology, and pain management. The company has seven manufacturing facilities in India and Mauritius, with two approved by the...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Mannalal B Agrawal
ISIN
INE031B01049
Website
https://www.ajantapharma.com
Ajanta Pharma Balance Sheet Screener
Screen AJANTPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 5,015 | 4,638 | 4,679 | 4,056 | 3,779 | 3,319 | 2,696 | 2,449 | 1,848 | 1,481 |
| Current Assets | 2,843 | 2,731 | 2,834 | 2,265 | 2,028 | 1,642 | 1,180 | 1,224 | 851 | 764 |
| Fixed Assets | 1,762 | 1,479 | 1,496 | 1,512 | 1,541 | 1,472 | 1,178 | 1,053 | 589 | 452 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 229 | 175 | 152 | 144 | 135 | 114 | 73 | 61 | 33 | 38 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 3,790 | 3,567 | 3,388 | 3,264 | 2,996 | 2,599 | 2,245 | 2,041 | 1,568 | 1,172 |
| Share Capital | 25 | 25 | 25 | 17 | 17 | 18 | 18 | 18 | 18 | 18 |
| Reserves & Surplus | 3,765 | 3,542 | 3,363 | 3,247 | 2,978 | 2,581 | 2,228 | 2,024 | 1,550 | 1,154 |
Ajanta Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Ajanta Pharma income statement and profit fundamentals.
Analyze AJANTPHARM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Ajanta Pharma share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,400 | 1,413 | 1,329 | 1,189 | 1,177 | 1,206 | 1,171 | 1,090 | 1,119 | 1,050 | 1,053 | 919 | 1,007 | 978 | 984 |
| Expenses | 993 | 1,026 | 951 | 873 | 825 | 876 | 815 | 776 | 791 | 738 | 750 | 733 | 802 | 742 | 729 |
| EBITDA | 407 | 387 | 378 | 315 | 351 | 331 | 357 | 314 | 328 | 312 | 303 | 186 | 205 | 237 | 255 |
| Operating Profit % | 28.00% | 24.00% | 27.00% | 25.00% | 28.00% | 26.00% | 29.00% | 26.00% | 28.00% | 28.00% | 27.00% | 17.00% | 17.00% | 21.00% | 23.00% |
| Depreciation | 44 | 43 | 41 | 40 | 36 | 34 | 34 | 34 | 34 | 34 | 33 | 33 | 33 | 33 | 32 |
| Interest | 5 | 3 | 5 | 6 | 8 | 6 | 1 | 2 | 3 | 2 | 1 | 1 | 3 | 1 | 1 |
| Profit Before Tax | 359 | 341 | 331 | 269 | 307 | 290 | 322 | 278 | 291 | 276 | 269 | 152 | 168 | 203 | 222 |
| Tax | 85 | 81 | 76 | 44 | 75 | 74 | 76 | 75 | 81 | 81 | 61 | 30 | 34 | 46 | 47 |
| Net Profit | 274 | 260 | 255 | 225 | 233 | 217 | 246 | 203 | 210 | 195 | 208 | 122 | 135 | 157 | 175 |
| EPS | 21.91 | 20.83 | 20.44 | 18.00 | 18.60 | 17.27 | 19.54 | 16.10 | 16.68 | 15.51 | 16.53 | 9.54 | 10.50 | 12.22 | 13.63 |
Ajanta Pharma Cash Flow Screener - Liquidity Fundamentals
Screen AJANTPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,157 | 785 | 792 | 562 | 576 | 457 | 375 | 281 | 609 | 326 |
| Investing Activities | -377 | 65 | -560 | -74 | -282 | -224 | -223 | -256 | -383 | -209 |
| Financing Activities | -733 | -1,051 | -108 | -460 | -318 | -129 | -148 | 0 | -202 | -117 |
| Net Cash Flow | 47 | -201 | 124 | 28 | -24 | 104 | 4 | 25 | 24 | 0 |
Ajanta Pharma Shareholding Pattern Screener
See Ajanta Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Ajanta Pharma promoter holding and ownership changes for AJANTPHARM on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 66.25% | 66.25% | 66.26% | 66.26% | 66.26% | 66.26% | 66.27% | 66.21% |
| FII Holding | 7.98% | 8.53% | 8.86% | 8.86% | 9.26% | 9.11% | 8.36% | 8.54% |
| DII Holding | 18.58% | 17.90% | 17.50% | 17.48% | 17.02% | 17.10% | 17.41% | 17.49% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% |
| Public Holding | 6.44% | 6.53% | 6.59% | 6.63% | 6.67% | 6.71% | 7.08% | 6.91% |
| Other Holding | 0.76% | 0.79% | 0.79% | 0.76% | 0.79% | 0.80% | 0.86% | 0.84% |
| Shareholder Count | 65,409 | 67,785 | 68,882 | 70,827 | 66,896 | 64,315 | 70,316 | 55,488 |
Ajanta Pharma Share Dividend Screener - Share Yield Analysis
Check Ajanta Pharma dividend history with payout and yield data.
View Ajanta Pharma dividend details including ex-dates and amounts for AJANTPHARM stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹28.00 | 1.00% |
| 2024-March | ₹51.00 | 1.94% |
| 2023-March | ₹7.00 | 0.31% |
| 2022-March | ₹9.50 | 0.79% |
| 2021-March | ₹9.50 | 0.79% |
| 2020-March | ₹13.00 | 1.09% |
| 2019-March | ₹9.00 | 0.99% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹13.00 | 1.40% |
Ajanta Pharma Stock Index Membership
See which indices include Ajanta Pharma stock.
Check AJANTPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 500
NIFTY LARGEMID250
NIFTY M150 QLTY50
NIFTY MIDCAP 150
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50
NIFTY500 SHARIAH
NIFTYM150MOMNTM50
Ajanta Pharma Market Events Screener - Corporate Actions
Get Ajanta Pharma corporate actions including splits, bonuses, and buybacks.
Check Ajanta Pharma stock events that may affect AJANTPHARM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-30 | 2026-01-30 | Quarterly Result Announcement | NA | -2.63% |
| 2025-11-10 | 2025-11-10 | Dividend | ₹ 28.00 /share | 2.50% |
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | 0.20% |
| 2025-07-28 | 2025-07-28 | Quarterly Result Announcement | NA | 3.00% |
| 2025-07-17 | 2025-07-17 | Annual General Meeting | NA | 5.31% |
| 2025-04-30 | 2025-04-30 | Quarterly Result Announcement | NA | 3.24% |
| 2025-01-30 | 2025-01-30 | Quarterly Result Announcement | NA | -8.46% |
| 2024-11-06 | 2024-11-06 | Dividend | ₹ 28.00 /share | 4.74% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -11.03% |
| 2024-07-18 | 2024-07-18 | Annual General Meeting | NA | -8.03% |
| 2024-05-30 | 2024-06-05 | Buyback | 2770 | -5.13% |
| 2024-02-08 | 2024-02-08 | Dividend | ₹ 26.00 /share | 6.89% |
| 2023-08-04 | 2023-08-04 | Dividend | ₹ 10.00 /share | 11.34% |
| 2023-08-04 | 2023-08-04 | Dividend | ₹ 15.00 /share | 11.34% |
| 2023-03-24 | 2023-03-31 | Buyback | 1425 | -5.17% |
Ajanta Pharma Competitors Screener - Peer Comparison
Screen AJANTPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 430,345 | 39.32 | 54,729 | 9.71% | 10,980 | 56.35 |
| Divis Laboratories | 159,215 | 64.39 | 9,712 | 18.67% | 2,191 | 39.57 |
| Torrent Pharmaceuticals | 144,367 | 64.00 | 11,539 | 6.99% | 1,911 | 49.85 |
| Dr Reddys Laboratories | 106,975 | 19.68 | 33,741 | 16.73% | 5,725 | 49.71 |
| Lupin | 106,653 | 22.98 | 22,910 | 13.74% | 3,306 | 56.95 |
| Cipla | 100,349 | 22.17 | 28,410 | 7.12% | 5,291 | 34.82 |
| Zydus Life Science | 90,229 | 18.09 | 23,511 | 18.55% | 4,615 | 49.23 |
| Mankind Pharma | 84,163 | 46.25 | 12,744 | 20.90% | 2,007 | 44.70 |
| Aurobindo Pharma | 76,329 | 21.80 | 32,346 | 9.43% | 3,484 | 63.55 |
| Alkem Laboratories | 63,902 | 26.83 | 13,458 | 3.70% | 2,216 | 45.83 |
Ajanta Pharma Company Announcements - News Screener
Screen AJANTPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-31 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-30 | Closure of Trading Window | - |
| 2026-03-27 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-09 | Participation In Investor Conference | - |
| 2026-03-06 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-02-23 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-02-17 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-02-10 | Rumour verification - Regulation 30(11) | - |
| 2026-02-06 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-02 | Participation In Investor Conference | - |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-01-30 | Intimation Of Vesting And Cash Settlement Of Stock Appreciation Rights (Sars) And Cancellation Of Employee Stock Options (Esops) | - |
| 2026-01-30 | Board Meeting Outcome for Board Meeting Outcome | - |
| 2026-01-30 | Unaudited Financial Results For Quarter Ended 31St December 2025. | - |
| 2026-01-20 | Rumour verification - Regulation 30(11) | - |
| 2026-01-13 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-01-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-12 | Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter Ended 31St December 2025. | - |